Midatech Pharma has today announced that it has selected wholly owned candidate compound MTR104 to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018.
“The programme is focused on advanced liver cancer where current chemotherapeutic treatment options are limited and the typical survival period is six months,” the company said.
Midatech is pursuing improved forms of cancer therapy based on combining marketed chemotherapeutic medicines with tumour-targeting molecules or peptides on the same nanoparticle-based conjugate.
“The aim is to allow highly toxic drugs to be specifically targeted to and delivered at the tumour cells while sparing normal tissue, thereby reducing side effects and enhancing efficacy.”
Story provided by StockMarketWire.com